WallStSmart

Synnex Corporation (SNX)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Synnex Corporation generates 25060% more annual revenue ($65.14B vs $258.90M). SNX leads profitability with a 1.5% profit margin vs -15.5%. SNX earns a higher WallStSmart Score of 66/100 (B-).

SNX

Strong Buy

66

out of 100

Grade: B-

Growth: 7.3Profit: 5.0Value: 7.3Quality: 5.8
Piotroski: 5/9Altman Z: 2.45

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SNXUndervalued (+79.0%)

Margin of Safety

+79.0%

Fair Value

$809.04

Current Price

$224.04

$585.00 discount

UndervaluedFair: $809.04Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SNX3 strengths · Avg: 8.7/10
EPS GrowthGrowth
104.4%10/10

Earnings expanding 104.4% YoY

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
18.1%8/10

18.1% revenue growth

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

SNX3 concerns · Avg: 2.7/10
Profit MarginProfitability
1.5%3/10

1.5% margin — thin

Operating MarginProfitability
2.9%3/10

Operating margin of 2.9%

Free Cash FlowQuality
$-929.01M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : SNX

The strongest argument for SNX centers on EPS Growth, Price/Book, Revenue Growth. Revenue growth of 18.1% demonstrates continued momentum. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : SNX

The primary concerns for SNX are Profit Margin, Operating Margin, Free Cash Flow. Thin 1.5% margins leave little buffer for downturns.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

SNX profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor ELECTRONICS & COMPUTER DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SNX scores higher overall (66/100 vs 41/100) and 18.1% revenue growth. ZEPP offers better value entry with a 48.6% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Synnex Corporation

TECHNOLOGY · ELECTRONICS & COMPUTER DISTRIBUTION · USA

SYNNEX Corporation provides business process services in the United States and internationally. The company is headquartered in Fremont, California.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?